Biomerieux Sustainability Profile
bioMérieux, a global leader in in vitro diagnostics, is headquartered in France and operates extensively across Europe, North America, and Asia. Founded in 1963, the company has consistently innovated in the fields of microbiology and molecular biology, achieving significant milestones such as the development of the first automated microbiology system. Specialising in diagnostic solutions for infectious diseases, bioMérieux offers a range of unique products, including rapid tests and automated systems that enhance laboratory efficiency and accuracy. Their commitment to quality and innovation has solidified their position as a trusted partner in healthcare, with notable achievements in improving patient outcomes through timely diagnostics. With a strong focus on research and development, bioMérieux continues to lead the way in advancing diagnostic technologies worldwide.
DitchCarbon Score
How does Biomerieux's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Biomerieux's score of 82 is higher than 88% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Biomerieux's reported carbon emissions
In 2024, bioMérieux reported total carbon emissions of approximately 1,183,000 kg CO2e, with Scope 1 emissions at about 22,000 kg CO2e, Scope 2 emissions at approximately 34,000 kg CO2e, and significant Scope 3 emissions of around 1,127,000 kg CO2e. The company has set ambitious targets to reduce its greenhouse gas emissions, committing to a 63% reduction in absolute Scope 1 and 2 emissions by 2034, using 2019 as the baseline year. Additionally, bioMérieux aims for 67% of its suppliers to have science-based targets by 2026. In 2023, the company reported total emissions of about 1,185,000 kg CO2e globally, with Scope 1 emissions at approximately 23,000 kg CO2e and Scope 2 emissions at around 38,000 kg CO2e. The Scope 3 emissions for that year were significant, at about 1,124,000 kg CO2e. The reduction initiatives include a near-term target of a 50% reduction in Scope 1 and 2 emissions by 2030 compared to 2019 levels. These commitments are part of bioMérieux's broader sustainability strategy, which is aligned with the Science Based Targets initiative (SBTi) and reflects the company's dedication to addressing climate change and reducing its carbon footprint. The emissions data is cascaded from the parent company, bioMérieux S.A., ensuring consistency in reporting and accountability across the corporate structure.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 31,000,000 | 00,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000 | 00,000 |
| Scope 2 | 35,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 241,000,000 | 000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000 | 0,000,000 |
How Carbon Intensive is Biomerieux's Industry?
How Carbon Intensive is Biomerieux's Location?
Biomerieux's Scope 3 Categories Breakdown
Biomerieux's Scope 3 emissions, which increased by 0% last year and decreased by approximately 100% since 2018, demonstrating supply chain emissions tracking. Their carbon footprint includes suppliers and value chain emissions, with Scope 3 emissions accounting for 3% of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 54836% of Scope 3 emissions.
Top Scope 3 Categories
Biomerieux's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Biomerieux has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Ortho Clinical Diagnostics Holdings plc
Thermo Fisher Scientific
Frequently Asked Questions
Common questions about Biomerieux's sustainability data and climate commitments